Eiken Chemical Co., Ltd. revised consolidated and non consolidated earnings guidance for the first six months of fiscal year ending September 30, 2017. For the period, the consolidated basis, company excepts expects operating income of ¥2,280 million, ordinary income of ¥2,310 million and net income attributable to shareholders of parent company of ¥1,680 million or ¥91.71 per share on net sales of ¥17,600 million compared to operating income of ¥1,400 million, ordinary income of ¥1,400 million and net income attributable to shareholders of parent company of ¥1,000 million or ¥54.60 per share on net sales of ¥18,000 million as previously forecasted. For the period, the non-consolidated basis, company excepts expects operating income of ¥2,320 million, ordinary income of ¥2,340 million and net income of ¥1,700 million or ¥92.80 per share on net sales of ¥17,600 million compared to operating income of ¥1,450 million, ordinary income of ¥1,450 million and net income of ¥1,050 million or ¥57.33 per share on net sales of ¥17,920 million as previously forecasted. Reason for Revision: Sales: Regarding overseas sales, although it is expected to increase compared to the previous fiscal year, it is expected to be lower than initially forecast due to sluggish sales of fecal immunochemical test reagents and LAMP reagent sales. Regarding domestic sales, it is expected as originally anticipated. Profit will significantly increase due to that the development cost-about ¥750 million of the compact fully automated genetic testing device scheduled in this second quarter consolidated accounting period will be carried over to the fourth quarter, and also the cost reduction by efficient use.